Amryt trio join Poolbeg leadership team

Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi.

The new recruits include David Allmond, former chief business officer at Amryt, who will take on the same role at Poolbeg from December 1.

Previously, Mr Allmond acquired the distribution rights for Lojuxta (lomitapide) for Europe and the Middle East in 2016. The lipid-lowering agent subsequently became Amryt’s first approved, revenue-generating product.